Keyphrases
Advanced Cancer
100%
Tumor mutational Burden
100%
Immune Checkpoint Inhibitors
58%
Hazard Ratio
58%
Upper Confidence Bound
58%
Overall Survival
25%
Programmed Death-ligand 1 (PD-L1)
16%
Clinical Outcomes
16%
Progression-free Survival
16%
Time to Progression
16%
TEMPUS
16%
Advanced Solid Tumors
16%
Cancer Types
8%
Histology
8%
Large Cohort
8%
Non-small Cell Lung Cancer (NSCLC)
8%
U.S. Food
8%
Cell Death
8%
Observational Data
8%
Cytotoxic T-lymphocyte antigen-4 (CTLA-4)
8%
Next-generation Sequencing
8%
Pembrolizumab
8%
Bladder Cancer
8%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
8%
Free Time
8%
Community Site
8%
Overall Survival Benefit
8%
Cancer Site
8%
Cancer Hazard
8%
Microsatellite Stable
8%
Blood Tumor mutational Burden
8%
Targeted Gene Panel
8%
L1 Stability
8%
PD-1/PD-L1 Immune Checkpoint Inhibitors
8%
Pharmacology, Toxicology and Pharmaceutical Science
Advanced Cancer
100%
Immunotherapy
100%
Neoplasm
100%
Immune Checkpoint Inhibitor
61%
Overall Survival
30%
Cohort Study
15%
Malignant Neoplasm
15%
Progression Free Survival
15%
Solid Malignant Neoplasm
15%
Biological Marker
7%
Lung Cancer
7%
Pembrolizumab
7%
Bladder Cancer
7%
Programmed Death 1 Ligand 1
7%
Head and Neck Squamous Cell Carcinoma
7%